Conference Track

Hepatitis Coinfection and Opportunistic Diseases

Source: CCO Independent Conference Coverage of the 2004 International AIDS Conference*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Isoniazid Prophylaxis in HIV-Infected Children Reduces Number of Deaths By Half in Area With High Tuberculosis Prevalence
Hepatitis C Virus (HCV) Coinfection Not Associated With Decreased Survival in CDC Cohort
Adefovir Safe and Effective in HIV/HBV-Coinfected Patients with Lamivudine-Resistant HBV After 4-Year Pilot Study
HIV Infection Independently Associated With Poorer Treatment Outcomes in Women With Cervical Cancer in Nairobi
Anal Pap Screening Has High Sensitivity But Low Specificity in HIV-infected Men in San Francisco
High Incidence of Tuberculosis in HAART-Treated Patients in Soweto
Early Assessment of Response to Hepatitis Therapy in HCV/HIV Coinfection Not Possible Before 12 Weeks
Use of Lopinavir/Ritonavir in Patients Coinfected with HIV and Hepatitis B or C Effective But Associated With Elevated Liver Enzymes
Peginterferon/Ribavirin Superior to Interferon/Ribavirin in HIV/HCV-Coinfected Patients Through 72 Weeks
HCV/HIV-1 Coinfection Associated With Blunted CD4+ Cell Response
Lack of Early Virologic Response to Pegylated-Interferon Plus Ribavirin Predictive of Treatment Failure in HIV/HCV-Coinfected Patients
HIV-Infected Children at Risk for Immune Reconstitution Inflammatory Syndrome
HAART Reduces Risk of OIs Independent of CD4+ Cell Count

Expert Analysis

Hepatitis Coinfection and Opportunistic Diseases

Program Director: John P. Phair, MD

Faculty:

Richard E. Chaisson, MD
Andrew T. Pavia, MD
Bruce Polsky, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe new findings on treatment of tuberculosis, immune reconstitution inflammatory syndrome, toxoplasmosis, and other opportunistic infections in HIV-infected patients
Discuss the impact of antiretroviral therapy on the liver in HBV- and HCV-coinfected patients
Review recent data on the treatment of HIV/HCV-coinfected patients with pegylated interferon + ribavirin regimens

Earn CME credit by reading the expert analysis and commentary on coinfection. Topics covered include:

Survival of HCV-Coinfected Patients
12-Week Virologic Response and Outcome in HCV-Coinfected Patients
Lopinavir/Ritonavir in Hepatitis B Virus (HBV)- and HCV-Coinfected Patients
Adefovir in HBV-Coinfected Patients
Isoniazid (INH) for Tuberculosis (TB) Prophylaxis
Efavirenz Dosing With Concomitant Rifampin
Toxoplasmosis and Other OIs
Immune Reconstitution Inflammatory Syndrome (IRIS)
Anal Dysplasia

CME CREDIT INFORMATION

Release Date: 08/19/04

Expiration Date: 08/18/05

Physicians: maximum of 2.0 AMA PRA Category 1 Credits™

Registered Nurses: 2.6 Nursing CE credits

Pharmacists: 2.25 contact hours (0.23 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.